You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 29, 2014

Food Labeling: A Recent Change in the Thai Paradigm

Informed Counsel

In response to consumers paying more attention to their dietary nutritional values, the food industry has taken steps to alter its approach to food product labeling. Labels that stipulate nutrient levels in food products (e.g., claiming low fat, high vitamin C, etc.) are now a common sight on food packaging. The Thai Food and Drug Administration (FDA) has, however, set certain criteria that must be met in order to make such nutritional claims and statements. Meanwhile, comparative claims, such as “the best,” “the most,” “the first,” etc., are prohibited, as the Thai FDA considers these claims to be difficult to prove.

The Thai FDA has issued legislation on “premium labeling,” a form of labeling that allows food producers to grade their food products, thus protecting their rights and the rights of consumers. The word “premium” on a food product label indicates that the food product possesses special qualities—qualities that the food producer must provide. Use of the word “premium” is subject to the approval of the Thai FDA. Such approval is obtained by citing evidence in support of the food’s “premium” quality (e.g., the food has been certified as organic, it has a geographical indication, or it has special ingredients). The first food products that received such approval were pasteurized milk and plain-fluid milk, both of which contain higher levels of milk protein, fat, and nonfat milk solids, as compared to other similar products.

Nutritional Labeling

Nutrition tables can be presented in three different formats: “full,” “short,” and “parallel.” The Ministry of Public Health’s Notification requires each table to contain certain information such as the amount of food per serving size, number of serving sizes per unit, nutrient content, and percentage of Thai Recommended Daily Intake (RDI) for each nutrient, per serving size, per day. A full format nutrition table must contain at least the following 15 mandatory nutrients:

  1. Total energy
  2. Energy from fat
  3. Total fat
  4. Saturated fat
  5. Cholesterol
  6. Protein
  7. Total carbohydrate
  8. Fiber
  9. Sugar
  10. Sodium
  11. Vitamin A
  12. Vitamin B1
  13. Vitamin B2
  14. Calcium
  15. Iron

However, if 8 or more of these 15 nutrients are low enough to be considered nonexistent, a short-format nutrition label can be used.

In the case that the food products must be mixed with other ingredients and/or processed according to the parallel label format, nutrition tables can be used to compare the nutritional values before and after preparation of the food product.

GDA Labeling

Obesity and related noncommunicable diseases have become global health concerns. The FDA has approached these issues by presenting nutritional information in recommended Guidelines of Daily Amounts (GDA), which aim to inform consumers of the amount of calories, sugars, fats, and sodium in food that they should be consuming daily. These guidelines are already used for some ready-to-eat foods, including fried or baked potato chips, crackers or biscuits, and wafers with fillings. These products must have nutrition and GDA labels, and must show the following statement: “Consume less and exercise for health.”

The GDA requires calories, sugars, fats, and sodium to be displayed on the front of the packaging by clearly declaring the nutrient content and the percentage of RDI per packaging unit, such as per sachet or carton. This information is shown in four cylindrical shapes. (See Fig. 2 below.)

Self-Regulating Product Labeling

On January 21, 2014, the FDA reclassified seven food products (sealed beverages, canned food, cow milk, flavored milk, fermented milk, milk products, and ice cream) as Standardized Foods. Under this category, food producers’ product labels must comply with FDA regulations and do not need label approval from the FDA. But some high-risk food products (e.g., medical foods, infant foods, modified milk for infants, weight-control foods, food additives, etc.) are still required to be submitted to and approved by the FDA for label preparation.

Which Food Labeling Requirements Have Changed?

Normally, a product label must provide the following information in Thai: (1) product name; (2) serial number; (3) importer’s or manufacturer’s name and address; (4) metric declaration of quantity; (5) ingredient list; and (6) production and expiration dates.

A noticeable change in the updated food labeling requirements is the addition of allergen information. Previously, the declaration of allergen information was on a voluntary basis. Now, it is mandatory to declare the allergen information of products that use the following ingredients:

  • Cereals that contain gluten, such as wheat, rye, spelt, or hybrid varieties, and their products;
  • Crustaceans and crustacean products;
  • Eggs and egg products;
  • Fish and fish products;
  • Peanuts, soybeans, and their products;
  • Milk and milk products (including lactose);
  • Hard-shelled nuts (such as pistachios), nuts, tree nuts (e.g., almonds, walnuts, pecans), and their products; and
  • Sulphite in concentrations of 10 mg/kg or more.

How to Comply with the Changed Regulations

Food regulations, particularly for food and nutrition labels, are becoming more dynamic and self-regulated than they have ever been in the past. Although this change in paradigm is beneficial for the food business, such autonomy means that food companies should have their labels carefully reviewed by lawyers and food consultants who have the proper technical and legislative knowledge, in order to fully comply with the law.

RELATED INSIGHTS​ 

January 5, 2026
On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam. According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity. Some of the key stipulations of Circular 57 are outlined below. Basis for Determining Technical Standards and Quality Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means: Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations; Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and Documentation evidencing compliance provided by the medical device owner. The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions. Classification of Medical Devices Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality. Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam. Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam. Outlook Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027. Holders of medical
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted
November 25, 2025
Food safety incidents can emerge without warning, requiring businesses to act swiftly to protect consumers and comply with regulatory obligations. Across Southeast Asia, Thailand, Vietnam, and Indonesia have each developed comprehensive food recall frameworks designed to ensure rapid removal of unsafe products from the market while holding businesses accountable for compliance failures. While these three jurisdictions share common objectives—protecting public health and ensuring food safety—each has crafted distinct regulatory approaches reflecting their unique administrative structures, enforcement priorities, and legal traditions. Understanding these differences is essential for food businesses operating in the region, as recall procedures, timelines, reporting requirements, and penalties vary significantly across borders. This guide, available through the button below, examines the food recall regulations in Indonesia, Thailand, and Vietnam, providing practical guidance on legal requirements, procedural steps, and compliance obligations in each market.